U.S. markets close in 4 hours 27 minutes
  • S&P 500

    4,226.42
    -57.32 (-1.34%)
     
  • Dow 30

    33,704.12
    -294.92 (-0.87%)
     
  • Nasdaq

    12,695.89
    -269.45 (-2.08%)
     
  • Russell 2000

    1,954.65
    -46.08 (-2.30%)
     
  • Crude Oil

    91.02
    +0.52 (+0.57%)
     
  • Gold

    1,760.90
    -10.30 (-0.58%)
     
  • Silver

    19.00
    -0.47 (-2.41%)
     
  • EUR/USD

    1.0050
    -0.0042 (-0.41%)
     
  • 10-Yr Bond

    2.9960
    +0.1160 (+4.03%)
     
  • GBP/USD

    1.1813
    -0.0120 (-1.01%)
     
  • USD/JPY

    137.0570
    +1.1950 (+0.88%)
     
  • BTC-USD

    21,384.91
    -2,059.52 (-8.78%)
     
  • CMC Crypto 200

    507.14
    -34.46 (-6.36%)
     
  • FTSE 100

    7,547.79
    +5.94 (+0.08%)
     
  • Nikkei 225

    28,930.33
    -11.77 (-0.04%)
     

GlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

GlaxoSmithKline (GSK) closed at $42.29 in the latest trading session, marking a +0.09% move from the prior day. This move outpaced the S&P 500's daily loss of 0.93%. Meanwhile, the Dow lost 0.43%, and the Nasdaq, a tech-heavy index, lost 0.17%.

GlaxoSmithKline will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.84, down 15.15% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $9.35 billion, down 17.33% from the year-ago period.

For the full year, our Zacks Consensus Estimates are projecting earnings of $3.96 per share and revenue of $42.75 billion, which would represent changes of +1.8% and -8.83%, respectively, from the prior year.

Investors might also notice recent changes to analyst estimates for GlaxoSmithKline. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.63% lower. GlaxoSmithKline is currently a Zacks Rank #3 (Hold).

The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 165, which puts it in the bottom 35% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
GSK plc (GSK) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research